World Health Organization (WHO Expert Committee on Biological Standardization), 2004: WHO 2004 guidance on viral inactivation of plasma products recognises methylene-blue-treated plasma (MB-plasma) as a validated photodynamic inactivation method with tabulated virus-kill data, while recording that the dye and its reaction products are mutagenic in bacteria and that European regulators requested mammalian genotoxicity data and validated removal filters.
Because it is well known that methylene blue and its reaction products are mutagenic (genotoxic) in bacteria
PDF page 54 (methylthioninium-plasma section)
World Health Organization (WHO Expert Committee on Biological Standardization), 2004: WHO 2004 guidance on viral inactivation of plasma products recognises methylene-blue-treated plasma (MB-plasma) as a validated photodynamic inactivation method with tabulated virus-kill data, while recording that the dye and its reaction products are mutagenic in bacteria and that European regulators requested mammalian genotoxicity data and validated removal filters. C10 WHO – blood safety guidance. The annex defines 'MB-plasma' as 'Methylene blue-treated plasma intended as a substitute for fresh frozen plasma' and tabulates inactivation of VSV, SIV, Semliki Forest, HSV, West Nile, Sindbis, BVDV and HIV by 1 mM methylene blue plus white light for one hour (Table 15). The quoted sentence sets out the regulatory concern; the span ends before a hyphenation break in the PDF and the sentence continues in the document. No patients and no clinical dose recommendations. Funder: WHO. Conflicts not applicable. Bearing PARTLY: WHO recognises the method and records a genotoxicity caveat in the same document. Study type: regulatory record.
